Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease

Novo Nordisk in the NEWS

Novo Nordisk (NVO) and Cardior Pharmaceuticals announced that Novo Nordisk agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.